Primary squamous cell carcinoma associated with ovarian endometriosis: a case report and literature review

Yamakawa Y, Yoshihiro Yamakawa, Michiyo Ushijima, Ushijima M, Kato K, Kiyoshi Kato
International journal of clinical oncology · 2011 · vol. 16(6) , pp. 709–713 · doi:10.1007/s10147-011-0189-3 · PMID:21301917 · W1974077646
article OA: closed CC0 ⤵ 5 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-06-13 ⓘ

This case report describes a patient with primary ovarian squamous cell carcinoma associated with endometriosis treated with paclitaxel–carboplatin, who initially responded but later recurred and was resistant to further chemotherapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text ⓘ

This paper is a case report and literature review describing primary squamous cell carcinoma (SCC) of the ovary associated with endometriosis in a 45-year-old woman, treated after stage IIIc optimal surgery with six courses of paclitaxel–carboplatin at 3-week intervals. The patient tolerated the chemotherapy and remained without evidence of disease during first-line treatment, but recurred two months later and the tumor showed resistance to subsequent second-line and third-line chemotherapy, leading to death 15 months after surgery. The authors note the rarity of this disease and that insufficient information exists to determine optimal postoperative treatment, with further studies needed to clarify true efficacy. This paper is centrally about endometriosis—specifically ovarian endometriosis-associated primary ovarian squamous cell carcinoma and the reported response to paclitaxel–carboplatin.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Primary squamous cell carcinoma (SCC) associated with ovarian endometriosis is extremely rare and has a poor prognosis due to insufficient information on the optimal postoperative treatment. Here, we describe the response of this tumor to the administration of paclitaxel-carboplatin. A 45-year-old woman diagnosed with stage IIIc primary SCC of the ovary associated with endometriosis underwent optimal surgery followed by six courses of chemotherapy at 3-week intervals with paclitaxel and carboplatin. She tolerated the chemotherapy well and remained without evidence of disease during first-line chemotherapy. Two months later, she was readmitted with recurrence of a pelvic tumor. Although she was treated with chemotherapy (weekly paclitaxel and chemotherapeutic regimen of irinotecan + mitomycin C), the tumor was resistant to second-line and third-line chemotherapy and she died 15 months after surgery. Paclitaxel-carboplatin administration may be an effective treatment for primary SCC of the ovary but further studies are required to investigate it true efficacy in the treatment of this disease.
Full text 3,013 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Primary squamous cell carcinoma (SCC) associated with ovarian endometriosis is extremely rare and has a poor prognosis due to insufficient information on the optimal postoperative treatment. Here, we describe the response of this tumor to the administration of paclitaxel–carboplatin. A 45-year-old woman diagnosed with stage IIIc primary SCC of the ovary associated with endometriosis underwent optimal surgery followed by six courses of chemotherapy at 3-week intervals with paclitaxel and carboplatin. She tolerated the chemotherapy well and remained without evidence of disease during first-line chemotherapy. Two months later, she was readmitted with recurrence of a pelvic tumor. Although she was treated with chemotherapy (weekly paclitaxel and chemotherapeutic regimen of irinotecan + mitomycin C), the tumor was resistant to second-line and third-line chemotherapy and she died 15 months after surgery. Paclitaxel–carboplatin administration may be an effective treatment for primary SCC of the ovary but further studies are required to investigate it true efficacy in the treatment of this disease. Similar content being viewed by others

References

Pins MR, Young RH, Daly WJ et al (1996) Primary squamous cell carcinoma of the ovary. Report of 37 cases. Am J Surg Pathol 20:823–833 Petterson F (1991) Annual report of the results of treatment in gynecological cancer. International Federation of Gynecology and Obstetrics, Stockholm McCoullough K, Floats ER, Falk HC (1946) Epidermoid carcinoma arising in an endometrial cyst of the ovary. Arch Pathol Lab Med 41:335 Lele SB, Piver MS, Barlow JJ et al (1977) Squamous cell carcinoma arising in ovarian endometriosis. Gynecol Oncol 6:290–293 Chen KTK, Weilert M (1982) Squamous cell carcinoma arising in endometriosis. Diagn Gynecol Obstet 4:343 Tetu B, Silva EG, Gershenson DM (1987) Squamous cell carcinoma of the ovary. Arch Pathol Lab Med 111:864–866 Naresh KN, Ahuja VK, Rao CR et al (1991) Squamous cell carcinoma arising in endometriosis of the ovary. J Clin Pathol 44:958–959 Campagnutta E, Sopracordevole F, Spolaor L et al (1994) Squamous cell carcinoma in ovarian endometriosis. A case report. J Reprod Med 39:557–560 Eltabbakh GH, Hempling RE, Recio FO et al (1998) Remarkable response of primary squamous cell carcinoma of the ovary to paclitaxel and cisplatin. Obstet Gynecol 91:844–846 Ohtani K, Sakamoto H, Masaoka N et al (2000) A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel–carboplatin administration. Gynecol Oncol 79:515–518 Conflict of interest None. Author information Authors and Affiliations Corresponding author About this article Cite this article Yamakawa, Y., Ushijima, M. & Kato, K. Primary squamous cell carcinoma associated with ovarian endometriosis: a case report and literature review. Int J Clin Oncol 16, 709–713 (2011). https://doi.org/10.1007/s10147-011-0189-3 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s10147-011-0189-3

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Antineoplastic Agents, Phytogenic Carboplatin Carcinoma, Squamous Cell Carcinoma, Squamous Cell Endometriosis Endometriosis Ovarian Neoplasms Ovarian Neoplasms Paclitaxel Antineoplastic Agents, Phytogenic Carboplatin Carcinoma, Squamous Cell Carcinoma, Squamous Cell Endometriosis Endometriosis Female Humans Laparotomy Middle Aged Neoplasm Recurrence, Local

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (9)

Cited by (5)

Source provenance

europepmc
last seen: 2026-08-15T06:15:18.721777+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:16:48.482574+00:00
unpaywall
last seen: 2026-08-15T06:29:46.044917+00:00
License: CC0 · commercial use OK